chufangao/CTO huggingface dataset:
Clinical trial NCT03934307: A Study to Evaluate ALN-AGT01 in Patients With Hypertension
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Dose and Active Comparator-Controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-AGT01 in Patients With Hypertension
Sponsor: Alnylam Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 124.0 (ACTUAL)
Number of arms: 7.0
Start date: 2019-05-01
Primary completion date: 2022-04-20
Completion date: 2023-01-04
Plan to share individual participant data: NO
Clinical trial NCT03336866: Study of Antibody for Methamphetamine Outpatient Therapy
Official title: STAMPOUT: Study of Antibody for Methamphetamine Outpatient Therapy
Acronym: STAMPOUT
Sponsor: InterveXion Therapeutics, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 77.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-03
Primary completion date: 2020-11-23
Completion date: 2021-03-09
Limitations and caveats: All participants were dosed with methamphetamine on a weekly basis following treatment with IXT-m200 or placebo. Thus, safety of IXT-m200 alone cannot be distinguished from the expected adverse events resulting from the methamphetamine doses. Variability of the responses on the drug effects questionnaires was much higher than anticipated. This resulted in insufficient power to detect differences between treated and control groups.
Plan to share individual participant data: YES
IPD sharing description: Final datasets are expected to contain pharmacokinetic data on IXT-m200 and METH, subjective effects data, immunogenicity totals, and safety data. No individually identifiable private information will be distributed.
IPD time frame: These datasets will be available for distribution following submission to the FDA of the Clinical Study Report and publication. They will be available for 2 years after the initial publication.
IPD access criteria: These datasets and associated documentation will be made available on CD by the Sponsor to requestors under a data sharing agreement that provides for: (1) a commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology and not distributing to third parties; and (3) a commitment to destroying or returning the data after analyses are completed. Requests should be sent to intervexion@gmail.com.
Clinical trial NCT04374552: Asymptomatic COVID-19 Trial
Official title: RCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without Antibiotics
Acronym: ACT
Sponsor: Rutgers, The State University of New Jersey (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The investigators have decided not to go forward with this protocol
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-05
Primary completion date: 2020-11-30
Completion date: 2021-04-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01734928: Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Official title: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Acronym: OPTIMISMM
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 559.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-01-07
Primary completion date: 2022-05-09
Completion date: 2022-05-13
Clinical trial NCT02427178: MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study
Official title: MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy) AHSCT (Allogeneic Hematopoietic Stem Cell Transplant) Safety Study
Acronym: MASS
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Poor enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-03-31
Primary completion date: 2022-06-30
Completion date: 2023-06-30
Plan to share individual participant data: YES
IPD sharing description: When applicable, we will submit a manuscript describing the results
Clinical trial NCT04131192: Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
Official title: A Phase Ib, Multi-center, Open-label Study of Z650 and Gemcitabine in Advanced Pancreatic Cancer
Sponsor: Sunshine Lake Pharma Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Combined with the analysis of the existing data of the trial, there was no obvious advantage compared with the clinical standard treatments, and the clinical trial was decided to be terminated based on the benefit of the subjects.
Enrollment: 13.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-11
Primary completion date: 2021-09-09
Completion date: 2021-09-09
Plan to share individual participant data: NO
Clinical trial NCT04133922: Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes
Official title: Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes
Acronym: KML001
Sponsor: University of Virginia (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: the study drug could not be obtained
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-10-14
Primary completion date: 2023-10-31
Completion date: 2024-10-31
Clinical trial NCT05665647: Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants
Official title: An Open Labe Study to Evaluate the Drug-Drug Interaction of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Adult Chinese Participants
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-12-29
Primary completion date: 2023-01-26
Completion date: 2023-02-14
Plan to share individual participant data: NO
Clinical trial NCT02965976: Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer
Official title: Double-Arm, Randomized Study of Botulinum Toxin Injection as a Pyloric Drainage Procedure for Minimally Invasive Esophagectomy (Phase II)
Sponsor: Roswell Park Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-30
Primary completion date: 2022-01-28
Completion date: 2022-04-28
Clinical trial NCT04521946: Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
Official title: A Pilot Study of Allogeneic Hematopoietic Cell Transplantation for Patients With High Grade Central Nervous System Malignancies
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No participants enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-14
Primary completion date: 2022-12-20
Completion date: 2022-12-20
Clinical trial NCT02931110: Study of IV CBL0137 in Previously Treated Hematological Subjects
Official title: A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects With Previously Treated Hematological Cancers
Sponsor: Incuron (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-01-31
Primary completion date: 2020-10-31
Completion date: 2020-10-31
Plan to share individual participant data: NO
Clinical trial NCT04338997: PK Study in Patients With Parkinson's Disease With IZD174
Official title: An Open-label Phase 1b Study to Evaluate the Pharmacokinetics and Pharmacodynamics in Plasma and Cerebrospinal Fluid (CSF), Safety and Tolerability of Oral IZD174 in Patients With Parkinson's Disease
Sponsor: Inflazome UK Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Strategic decision by Sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-31
Primary completion date: 2020-11-30
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT03191201: A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis.
Official title: A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age.
Acronym: DIAFER
Sponsor: University of Lausanne (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The reason for early termination is difficulties recruiting that caused a premature ending of financial resources ensuring protected time for research.
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-21
Primary completion date: 2020-03-09
Completion date: 2020-03-09
Plan to share individual participant data: NO
Clinical trial NCT04210245: Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
Official title: Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4)
Sponsor: NGM Biopharmaceuticals, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 160.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-03-23
Primary completion date: 2023-01-04
Completion date: 2023-02-23
Plan to share individual participant data: NO
Clinical trial NCT01208051: Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
Official title: Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 127.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-09-09
Primary completion date: 2020-02-01
Completion date: 2020-02-01
Clinical trial NCT02295722: GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
Official title: Infusional Gemcitabine and High-dose Melphalan (HDM) Conditioning Prior to (ASCT) Autologous Stem Cell Transplantation for Patients With Relapsed/Refractory Lymphoma
Acronym: GEMHDM2014
Sponsor: AHS Cancer Control Alberta (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: It did not show a significant benefit to justify completing the full target accrual.
Enrollment: 100.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-04-30
Primary completion date: 2023-02-28
Completion date: 2023-02-28
Plan to share individual participant data: NO
Clinical trial NCT03331562: A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
Official title: A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
Sponsor: Translational Genomics Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-27
Primary completion date: 2020-06-29
Completion date: 2020-07-10
Limitations and caveats: Due to lack of grant funding, the other exploratory objectives to assess the changes in tumor and/or tissue texture on imaging, and to monitor and compare gut microbial communities in both arms, have not yet been able to be accomplished. The Investigators are looking for some way to fund the exploratory objectives in the future.
Plan to share individual participant data: NO
Clinical trial NCT04243837: LYT-100 in Patients With BCRL
Official title: A Phase 2a Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of Deupirfenidone (LYT-100) in Patients With Breast Cancer-Related Upper Limb Secondary Lymphoedema
Sponsor: PureTech (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Primary objective/endpoint has been established, will not pursue development of the disease indication further
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-01
Primary completion date: 2022-09-09
Completion date: 2022-09-09
Plan to share individual participant data: NO
Clinical trial NCT03134638: A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
Official title: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
Sponsor: Syros Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business Decision
Enrollment: 107.0 (ACTUAL)
Number of arms: 6.0
Start date: 2017-05-12
Primary completion date: 2020-05-15
Completion date: 2020-06-24
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03434366: Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder
Official title: Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder
Sponsor: Guangzhou Women and Children's Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: The effects are not good
Enrollment: 50.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2018-01-20
Primary completion date: 2023-12-30
Completion date: 2023-12-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03312907: A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
Official title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 292.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-03-01
Primary completion date: 2020-05-29
Completion date: 2021-07-07
Baseline population: Baseline characteristics were presented for Intent-to-Treat Population.
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT04130802: OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
Official title: A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of Two Doses of OCS 01 Compared to Vehicle in the Treatment of Inflammation and Pain Following Cataract Surgery
Acronym: SKYGGN
Sponsor: Oculis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 153.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-27
Primary completion date: 2020-01-31
Completion date: 2020-01-31
Plan to share individual participant data: NO
Clinical trial NCT02541903: Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma
Official title: A Phase 2 Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Following Systemic Therapy
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: poor overall accrual
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-10-31
Primary completion date: 2019-01-26
Completion date: 2020-04-30
Baseline population: 1 patient expired after signing consent but before starting treatment
Limitations and caveats: This study was closed early due to poor enrollment.
Plan to share individual participant data: NO
Clinical trial NCT03083041: A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Official title: A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 210.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-03-22
Primary completion date: 2022-04-22
Completion date: 2022-05-20
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04381988: A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy
Official title: A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID)
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated based results of other studies and use of the new vaccine.
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-07
Primary completion date: 2021-04-21
Completion date: 2021-04-21
Baseline population: The study was terminated before more participants were accrued.
Plan to share individual participant data: YES
IPD sharing description: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Clinical trial NCT01750281: Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
Official title: A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)
Acronym: SELECT-2
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 212.0 (ACTUAL)
Number of arms: 3.0
Start date: 2012-12-18
Primary completion date: 2016-01-27
Completion date: 2022-10-31
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Clinical trial NCT01873833: Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
Official title: Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen
Sponsor: University of Southern California (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient accrual
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-07-29
Primary completion date: 2021-03-02
Completion date: 2021-03-02
Clinical trial NCT03478787: Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
Official title: A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 327.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-08
Primary completion date: 2020-07-08
Completion date: 2020-07-08
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT04220281: Comparison Between Two Drugs (Propofol and Nitroglycerin as a Hypotensive Agents During Endoscopic Sinus Surgery
Official title: Comparison of the Hypotensive Efficacy of Propofol Infusion Versus Nitroglycerin Infusion in Functional Endoscopic Sinus Surgery
Acronym: prop
Sponsor: Ain Shams University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: the number of patients needed for the study have been collected
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-01
Primary completion date: 2020-02-12
Completion date: 2020-02-12